Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04812262 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
A Phase 1 study, sponsored by Neuraly.
- Completed
- Registry status
- Phase 1
- Development phase
- 255
- Enrollment target
NCT04812262 is a Phase 1 study that has completed, run by Neuraly. The registered enrollment target is 255 participants.
The verdict
NCT04812262, a Phase 1 study, has completed, sponsored by Neuraly.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 255 participants
- Enrollment target
Study Summary
This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). The study will be conducted in 2 Parts (Part A and B), with up to 8 cohorts included in each part (Part A; Cohorts A1 to A8 and Part B; Cohorts B2 to B8).
Interventions
- DRUG Placebo
- DRUG DD01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2021-02-24 |
| Est. Completion | 2023-02-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04812262
The ClinicalTrials.gov registry entry for NCT04812262 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuraly, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04812262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04812262 about?
NCT04812262 is a clinical study titled "A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD". This is a Phase 1, first in human (FiH), randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study to investigate the safety, tolerability, PK and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 d...
What is the current status of trial NCT04812262?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 255 participants. The study started on 2021-02-24. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT04812262?
The interventions under investigation include: Placebo (DRUG), DD01 (DRUG).
Who is sponsoring clinical trial NCT04812262?
This trial is sponsored by Neuraly, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.